secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066440
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

ALX Oncology Reports Q1 2025 Financial Results, Updates on Evorpacept and ALX2004 Pipeline
--------------------------------------------------------------------------------

- Reported Q1 2025 net loss of $30.8M ($0.58 per share) compared to $35.6M in Q1 2024; cash runway extended into Q4 2026 with $107.0M in cash.
- Received IND clearance from FDA for ALX2004, a novel EGFR-targeted ADC; Phase 1 initiation expected mid-2025 with initial safety data in 1H 2026.
- Will not pursue U.S. registrational path for evorpacept in gastric cancer after FDA feedback that accelerated approval not feasible due to ENHERTU®.
- Discontinued evorpacept in combination with PADCEV® in urothelial cancer due to lack of improved efficacy in ASPEN-07 trial.
- Expect to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies mid-2025, with data milestones in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025066440/0000950170-25-066440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025066440/alxo-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer